Apheresis as Therapy
Aferetica is an Innovative Small and Medium-sized Enterprise (SME), founded by Managers with tens of years of experience in Dialysis, Intensive Care, Cardiology and Medical Devices.
The company proposes itself as a catalyst for the creation of a Network of Clinicians, Academics, Researchers and Institutions, to create and validate New Apheretic Therapies, even for unexplored clinical areas.
An integrated and innovative vision of apheretic therapies is the challenge to face for a real evolution of the cure.
APHERESIS
Contribute to research for the development, creation and diffusion of complete apheretic therapies.
TRANSPLANTATION
For a concrete breakthrough in organ availability and transplantation outcome.
CRITICAL CARE
Apheresis as therapy: new frontiers in critically ill patients.
Our Therapeutic Systems
Products, knowledges, therapeutic protocols and clinical research.
Last updates
Against the Sepsis a new powerful ally
We are proud to announce that from today the fight against the Sepsis, the world's leading cause of hospital death, has a new ally.
AREA CRITICA Congress
Bologna, Palazzo dei Congressi, 5th – 6th December
CytoSorb® Registry
CytoSorb® Registry is an independent international registry coordinated by the University Hospital of Jena and aimed at collecting data of all patients treated with CytoSorb®.